Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Earns Band 1 Recognition in Multiple Categories in 2025 Chambers USA Guide
News
Antitrust
Antitrust 101: Criminal Antitrust Enforcement in U.S. v. US Gypsum Co., 438 US 422 (1978)
Podcast
FTC Peeling Back the Layers of the Orange Book
Axinn Viewpoints
Intellectual Property
Patman Returns … and Retreats Again
Axinn Viewpoints
Antitrust
The Approach of Public and Private Enforcers to Data Use in the Financial Services Sector
Byline Articles
Antitrust
Axinn Successfully Reunites One of Its Pro Bono Clients, a Former Afghan Army Captain, with His Wife and Four Children
Pro Bono